Novavax (NVAX)
(Delayed Data from NSDQ)
$9.35 USD
-0.26 (-2.71%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $9.42 +0.07 (0.75%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.35 USD
-0.26 (-2.71%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $9.42 +0.07 (0.75%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
Zacks News
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $140.69, moving +1.78% from the previous trading session.
3 Small Biotechs in Focus on Promising Coronavirus Vaccine Data
by Zacks Equity Research
Pfizer (PFE) and AstraZeneca (AZN) announce promising data from early-stage coronavirus vaccine studies. Here we discuss three leading biotechs with potential to recshare price gains.
Vaxart's Soars YTD on Robust Coronavirus Vaccine Progress
by Zacks Equity Research
Vaxart's (VXRT) oral coronavirus vaccine candidate is chosen by Operation Warp Speed for a vaccine study. Last month, the company picked its lead COVID-19 vaccine candidate.
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $111.15, moving +1.07% from the previous trading session.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Novavax and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Novavax and Johnson & Johnson
The Zacks Analyst Blog Highlights: Etsy, TMobile US, Anthem, Novavax and Southwest Gas
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Etsy, TMobile US, Anthem, Novavax and Southwest Gas
Race to Coronavirus Vaccine Heats Up: 5 Stocks in Spotlight
by Tirthankar Chakraborty
Two experimental coronavirus vaccines, manufactured jointly by Pfizer and BioNTech, have received fast track status from the FDA.
Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (NVAX) Outperforming Other Medical Stocks This Year?
Novavax, Inc. (NVAX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Novavax, Inc. (NVAX).
Coronavirus to Cast a Pall Over Q2 Earnings: 5 Stocks to Stand Out
by Tirthankar Chakraborty
It will be prudent to invest in companies from the tech, healthcare and utility sectors, which are expected to have suffered less compared to others in Q2.
Emergent (EBS) Stock Up Year to Date on Coronavirus Vaccine Deals
by Zacks Equity Research
Emergent (EBS) inks deals with multiple companies to provide manufacturing services for helping them develop COVID-19 vaccine.
Biotech Stock Roundup: REGN Initiates Coronavirus Study, NVAX Surges & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Company News for Jul 8, 2020
by Zacks Equity Research
Companies In The News Are: WMT, NVAX, DOCU, REGN.
Novovax Up on $1.6B Federal Funding for Coronavirus Program
by Zacks Equity Research
Novovax (NVAX) is evaluating a coronavirus vaccine candidate, NVX-CoV2373, in a phase I/II study. A pivotal study is due to start in the fourth quarter.
Emergent's (EBS) 5-Year Deal to Back J&J's Coronavirus Vaccine
by Zacks Equity Research
Emergent BioSolutions (EBS) extends a five-year deal with J&J to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.
FDA Issues Guidance for Coronavirus Vaccine Developers
by Kinjel Shah
Around a dozen companies are developing a vaccine for the deadly coronavirus disease.
Top Leveraged ETFs of Last Week
by Sanghamitra Saha
Leveraged gold miners and treasury ETFs gained last week despite a market crash.
The Zacks Analyst Blog Highlights: Microvision, Veritone, Remark, Novavax and DCP
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microvision, Veritone, Remark, Novavax and DCP
Growth Investing Leads in 1H: 5 Top ETFs & Stocks
by Sweta Killa
Growth investing took a lead so far this year courtesy of massive money flowing into the economy.
The Zacks Analyst Blog Highlights: Zoom Video, Quidel, Zscaler, Datadog and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Zoom Video, Quidel, Zscaler, Datadog and Novavax
Fears of a Second Wave of Coronavirus are Aiding These 5 Stocks
by Anirudha Bhagat
Here we pick five stocks which have potentials to gain in situations if the stock market is hit by the second wave of the coronavirus pandemic.
Wall Street Readies for Best Quarter Ever: 5 Picks
by Tirthankar Chakraborty
The S&P 500 is up 21.2% so far in Q2 and is on pace for its biggest quarterly gain since Q1 of 1975. Similarly, the Nasdaq is up 31.6% since the end of Q1, putting it on pace for its second-best quarter ever.
5 Top-Ranked Stocks That Made Nasdaq Outperform in 1H
by Sweta Killa
The tech-heavy Nasdaq Composite Index has outperformed so far this year, having gained 12% in comparison to losses of 3.5%for the S&P 500 and 8.8% for Dow Jones.
5 Nasdaq Stocks That Have Returned More Than 100% YTD
by Aniruddha Ganguly
Here we discuss five Nasdaq-listed stocks that have gained more than 100% year to date and are well-poised to grow further on solid prospects.